Core Viewpoint - The company has adjusted the purchase price for its 2025 employee stock ownership plan from 4.41 CNY per share to 4.32 CNY per share due to the distribution of cash dividends [1][3][5] Group 1: Employee Stock Ownership Plan - The company held board and supervisory meetings on July 14, 2025, to approve the adjustment of the purchase price for the employee stock ownership plan [1][2] - The employee stock ownership plan was initially approved on April 29, 2025, with subsequent disclosures made on April 30 and May 15, 2025 [2][3] Group 2: Adjustment Details - The adjustment was necessitated by the cash dividend distribution, which was based on a total share capital of 837,982,631 shares, deducting 11,910,000 shares held in the repurchase account [3][5] - The adjusted purchase price formula is based on the initial price minus the per-share dividend amount, resulting in an adjusted price of approximately 4.32 CNY per share [3][5] Group 3: Impact and Compliance - The adjustment will not have a significant impact on the company's financial status or operational results, nor will it affect the stability of the management team or the implementation of the employee stock ownership plan [5] - The supervisory board has confirmed that the adjustment complies with relevant regulations and does not harm the interests of the company or its shareholders [5][6]

Core Viewpoint - The legal opinion letter from Anhui Tianhe Law Firm confirms that Hefei Xinhui Microelectronics Co., Ltd. has complied with necessary approvals and authorizations for its 2025 Employee Stock Ownership Plan (ESOP) adjustments, aligning with relevant regulations and guidelines [2][5][7]. Group 1: Legal Framework and Compliance - The law firm was commissioned to provide legal advice regarding the company's 2025 ESOP, based on various laws and regulations including the Company Law and Securities Law [2]. - The company conducted necessary meetings and obtained approvals from its board of directors, supervisory board, and shareholders for the ESOP adjustments on specified dates in 2025 [3][4][5]. Group 2: Adjustment Details - The adjustment was necessitated by the company's 2024 annual profit distribution plan, which involved a cash dividend of approximately 0.0936 yuan per share, calculated based on the adjusted total share capital [5][6]. - The adjusted purchase price for the shares under the ESOP is approximately 4.32 yuan per share, reflecting the cash dividend deduction from the initial purchase price [6]. Group 3: Conclusion - The law firm concludes that the company has fulfilled all necessary approvals for the ESOP adjustments, which are in compliance with the relevant guidelines [7].

员工持股计划的核心问题，是上市公司治理中内部人与外部投资者利益平衡的问题。诚意药业计划中， 董事、高管及核心骨干作为主要参与对象，其利益与公司短期业绩高度绑定，而中小投资者更关注长期 价值创造。当解锁条件在设定上偏向更容易达成时，员工可能优先追求短期指标，导致公司战略偏离股 东价值最大化。 更为关键的是，员工持股计划允许以营业收入或净利润二选一作为考核标准，进一步降低了达标门槛。 在极端情况下，若公司通过降价促销等手段扩大营收但牺牲利润，仍可满足解锁条件，可能导致激励与 股东真实回报脱钩。 此外，员工持股计划的买入价格为5.02元/股，该价格虽然符合相关规定，但与市场实际股价相比存在 较大套利空间。这种无风险套利机制，实质上将股东利益让渡给员工，尤其当解锁条件宽松时，福利属 性远超激励功能。 从资金来源看，员工持股计划总额不超过4828.6356万元，资金来源包括员工合法薪酬、自筹资金以及 法律法规允许的其他方式，公司不提供财务资助。表面上看，员工承担了投资风险，但半价购股的确定 性收益已对冲了大部分风险。例如，若一年后股价维持当前水平，员工持股计划仅通过解锁即可获得超 100%的收益，远超普通投资者风险收益 ...

证券简称：金海通 证券代码：603061 天津金海通半导体设备股份有限公司 天津金海通半导体设备股份有限公司 二〇二五年七月 声 明 称"本持股计划"）系天津金海通半导体设备股份有限公司（以下简称"本公司"、 "公司"、"金海通"）依据《中华人民共和国公司法》《中华人民共和国证券法》 《关于上市公司实施员工持股计划试点的指导意见》《上海证券交易所上市公司 自律监管指引第 1 号——规范运作》等有关法律、行政法规、规章、规范性文件 和《公司章程》的规定，由公司董事会制定并审议。 强行分配等强制员工参加本持股计划的情形。 重要作用和影响的董事（不含独立董事）、监事、高级管理人员及骨干人员，首 次授予的员工总人数不超过 192 人，其中董事（不含独立董事）、监事、高级管 理人员为 8 人，具体参加人数根据员工实际缴款情况确定。预留授予人员指本持 -2- 本公司及董事会全体成员保证本持股计划及其摘要不存在虚假记载、误导性 陈述或重大遗漏，并对其真实性、准确性、完整性依法承担法律责任。 本方案主要条款与公司 2025 年 6 月 28 日公告的公司 2025 年员工持股计划 草案及其摘要内容一致。 风险提示 不确定。 ...

证券代码：688202 证券简称：美迪西 公告编号：2025-041 上海美迪西生物医药股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 回购方案首次披露日 2024/12/28，由公司实际控制人、时任董事长陈金 章先生，实际控制人、时任董事、总经理 CHUN-LIN CHEN 先生提议 回购方案实施期限 2025 年 1 月 14 日~2025 年 7 月 13 日 预计回购金额 5,000万元~10,000万元 回购价格上限 54元/股 √减少注册资本 回购用途 √用于员工持股计划或股权激励 □为维护公司价值及股东权益 实际回购股数 160.4487万股 实际回购股数占总股本比例 1.19% 实际回购金额 5,007.53万元 实际回购价格区间 27.76元/股~53.16元/股 一、回购审批情况和回购方案内容 上海美迪西生物医药股份有限公司（以下简称"公司"）分别于 2024 年 12 月 股东大会审议通过了《关于以集中竞价方式回购公司股份方案的议案》 ...

证券代码：001330 证券简称：博纳影业 公告编号：2025-039 号 博纳影业集团股份有限公司 关于 2025 年员工持股计划首次授予部分非交易过户完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 博纳影业集团股份有限公司（以下简称"博纳影业"或"公司"）于 2025 年 4 月 员工持股计划(草案)>及其摘要的议案》《关于 <博纳影业集团股份有限公司 ensp="ensp" 年员="年员"> 工持股计划管理办法>的议案》和《关于提请股东大会授权董事会办理公司 2025 年员工 持股计划有关事项的议案》等相关议案，同意公司实施 2025 年员工持股计划（以下简 称"本次员工持股计划"）。具体内容详见公司分别于 2025 年 4 月 25 日、2025 年 5 月 根据《关于上市公司实施员工持股计划试点的指导意见》及《深圳证券交易所上市 公司自律监管指引第 1 号——主板上市公司规范运作》等相关规定，现将本次员工持股 计划实施进展情况公告如下： 一、本次员工持股计划的股票来源及数量 （一）本次员工持股计划的股票来源 本次员工持股计划股票来源为公司 ...

Summary of Key Points Core Viewpoint - The company, Fujian Yuanli Activated Carbon Co., Ltd., has approved a share repurchase plan to buy back its own shares using its own funds, with a total budget between RMB 50 million and RMB 80 million, and a maximum repurchase price of RMB 17.00 per share within a 12-month period [1]. Share Repurchase Plan - The board of directors approved the share repurchase plan on July 12, 2024, allowing the company to repurchase shares through centralized bidding [1]. - The total amount allocated for the repurchase is between RMB 50 million and RMB 80 million, with a maximum price of RMB 17.00 per share [1]. Implementation Status - As of the latest announcement, the company has repurchased a total of 4,637,501 shares, representing 1.27% of the total share capital, with a total transaction amount of approximately RMB 59.99 million [2]. - The highest transaction price during the repurchase was RMB 13.68 per share, while the lowest was RMB 12.35 per share [2]. Compliance and Impact - The implementation of the repurchase plan does not significantly impact the company's financials, operations, research and development, or debt repayment capabilities [3]. - The share repurchase will not alter the company's control or its status as a listed company, and the share distribution remains compliant with listing requirements [3]. Share Capital Changes - Prior to the repurchase, the total share capital was 365,852,860 shares, which decreased to 364,210,360 shares after the repurchase [4]. - The company plans to cancel all unused repurchased shares, totaling 1,642,500 shares from previous repurchase activities [4]. Future Plans for Repurchased Shares - The repurchased shares will be stored in a dedicated account and are intended for employee stock ownership plans or equity incentive plans [7]. - If the repurchased shares are not utilized within 36 months, they will be legally canceled [7].

关于 国浩律师（杭州）事务所 浙江闰土股份有限公司 之法律意见书 地址：杭州市上城区老复兴路白塔公园 B 区 2 号、15 号国浩律师 楼 邮编：310008 Grandall Building, No.2＆No.15, Block B, Baita Park, Old Fuxing Road, Hangzhou, Zhejiang 310008, China 电话/Tel: (+86)(571) 8577 5888 传真/Fax: (+86)(571) 8577 5643 电子邮箱/Mail：grandallhz@grandall.com.cn 网址/Website：http://www.grandall.com.cn 二零二五年七月 国浩律师（杭州）事务所 法律意见书 国浩律师（杭州）事务所 关于 浙江闰土股份有限公司 之法律意见书 致：浙江闰土股份有限公司 根据浙江闰土股份有限公司（以下简称"闰土股份"、"公司"）与国浩律师 （杭州）事务所（以下称"本所"）签订的法律服务委托协议，本所接受闰土股 份的委托，根据《中华人民共和国公司法》 《中华人民共和国证券法》 《关于上市 公司实施员工持股计划试点的指导 ...

关于 2024 年员工持股计划锁定期届满的提示性公告 证券代码：002458 证券简称：益生股份 公告编号：2025-051 山东益生种畜禽股份有限公司 关于 2024 年员工持股计划锁定期届满的 提示性公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 山东益生种畜禽股份有限公司（以下简称"公司"）2024 年员工 持股计划（以下简称"本员工持股计划"）锁定期将于 2025 年 7 月 16 日届满。根据《关于上市公司实施员工持股计划试点的指导意见》 《深 圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范 运作》及《山东益生种畜禽股份有限公司 2024 年员工持股计划管理 办法》的相关规定，现将本员工持股计划锁定期届满的相关情况公告 如下： 一、本员工持股计划的基本情况和锁定期 公司第六届董事会第十九次会议和 2024 年第三次临时股东大会 审议通过了公司《<2024 年员工持股计划（草案）>及摘要》相关议案， 同意公司实施本员工持股计划。具体内容详见公司于 2024 年 6 月 26 日及 2024 年 7 月 13 日刊登在《中国证券报》 ...

Core Viewpoint - The implementation of the 2025 employee stock ownership plan by Zhejiang Chengyi Pharmaceutical Co., Ltd. is expected to enhance the alignment of interests between employees and shareholders, improve employee motivation, and contribute to the company's long-term sustainable development [1][2]. Summary by Sections Employee Stock Ownership Plan - The 2025 employee stock ownership plan aims to establish and improve the mechanism for sharing interests between employees and shareholders, thereby enhancing the company's competitiveness and cohesion among employees [1]. - The draft of the 2025 employee stock ownership plan complies with relevant regulations and does not harm the interests of the company or all shareholders [1]. - Participation in the employee stock ownership plan is based on voluntary compliance, with no forced participation or distribution among employees [1].